Journal of Clinical Oncology
Articles in this Issue
COBRA: Assessment of the efficacy of <sup>64</sup> Cu-SAR-bisPSMA using histopathology as reference standard in patients with biochemical recurrence of prostate cancer following definitive therapy.
44 Background: Accurate staging of recurrent prostate cancer (PC) is essential to inform the best treatment strategy. Prostate-specific membrane antigen (...
Gene expression signatures in biopsy cores as predictors of coexisting higher-grade disease in Gleason group 1 prostate cancer: Results from the Miami MAST prospective clinical trial.
239 Background: Despite several improvements in Active Surveillance (AS), pathologic reclassification remains frequent. Therefore, we examined if gene exp...
Inferring ECOG performance status (PS) using large language models in patients with advanced prostate cancer.
136 Background: The ECOG performance status (PS) is a critical measure for evaluating functional capacity and determining clinical trial eligibility in pa...
Evaluating the role of cancer-associated fibroblasts in T cell–mediated proinflammatory reprogramming of tumor associated macrophages in the prostate cancer tumor microenvironment.
248 Background: Tumor-associated macrophages (TAMs) have been implicated as a critical mediator of T cell exclusion and inhibition within the prostate TME...
GLP1R expression in prostate cancer patients and effects of GLP1R agonism on prostate cancer cells.
182 Background: As a disease of aging, metabolic co-morbidities are managed concurrently with prostate cancer. Recent FDA approvals have launched widespre...
Results from the prior treatment cohort of a phase I/II study of nivolumab and axitinib in patients with advanced renal cell carcinoma.
548 Background: Combination tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (IO) are an established standard of care for patients with...
The prognostic role of circulating tumor DNA (ctDNA) clearance as a biomarker in localized and metastatic renal cell carcinoma (RCC): A single-center experience.
570 Background: The use of ctDNA-based molecular residual disease detection represents a promising prognostic biomarker in multiple solid tumors, yet limi...
Evaluation of time to metastasis (TTM) from prostatectomy and survival in patients (pts) with metachronous metastatic hormone-sensitive prostate cancer (mHSPC) receiving androgen deprivation therapy (ADT) intensification: A real-world study.
100 Background: Metachronous mHSPC is associated with improved outcomes compared to synchronous (de novo) mHSPC. However, there are limited data on the ef...
Utilizing ChatGPT for assessing disease volume in patients (pts) with metastatic prostate cancer (mPC).
42 Background: Artificial intelligence (AI) has transformed many aspects of healthcare, particularly in medical imaging analysis. In mPC, accurate identif...
Assessing genomic instability (GI) by shallow whole-genome sequencing (sWGS) to predict PARP inhibitor (PARPi) response in metastatic castration-resistant prostate cancer (mCRPC).
194 Background: The heterogeneous efficacy of PARPi in patients with mCRPC and homologous recombination deficiency (HRd)-associated genetic alterations ha...
Real-world treatment patterns in patients diagnosed with metastatic castration-resistant prostate cancer in the US, 2018-2023.
74 Background: The treatment landscape in patients with metastatic castration-resistant prostate cancer (mCRPC) has evolved in recent years. This real-wor...
Impact of tumor burden on treatment patterns and outcomes in patients with locally advanced or metastatic urothelial carcinoma (la/mUC) treated with avelumab first-line maintenance (1LM).
764 Background: With the evolving treatment (tx) landscape in la/mUC, patient (pt) clinical characteristics are increasingly important when selecting syst...
Impact of COVID-19 pandemic on the treatment of prostate cancer in Brazilian public health system, comparing pre and post pandemic data.
373 Background: During the COVID-19 pandemic resources from the Brazilian Public Health System (BPHS) were directed to the treatment of COVID-19. The impa...
Efficacy and safety of SABR with TKI and IO therapy in patients with mRCC.
529 Background: Metastatic RCC is a deadly disease and TKI in combination with IO has become a standard therapy for most patients. But some of the pts may...
Clinical outcomes in metastatic bladder cancer associated with mutations in Trithorax-group protein genes.
835 Background: The Trithorax-group (TrxG) comprises a large family of multi-protein complexes that play a key role in epigenetic regulation, cell divisio...
Clinical outcomes of stage IIA/IIB seminoma treated with radiotherapy and chemotherapy: Should regional therapy be considered the preferred treatment approach?
629 Background: With the publication of the Surgery in Early Metastatic Seminoma Trial there has been increasing interest in the use of regional therapy a...
Prognostic significance of PSA in the outcomes of patients with high risk localized prostate cancer.
347 Background: Patients diagnosed with localized high-risk prostate adenocarcinoma (LHRPC) with high Gleason scores (8-10) and prostate-specific antigen...
Real-world clinical practice gaps in timely homologous recombination repair gene mutation (HRRm) testing and poly (ADP-ribose) polymerase inhibitor (PARPi) treatment of patients with metastatic castration resistant prostate cancer (mCRPC).
85 Background: Testing for HRRm is standard of care for all mCRPC patients to identify those eligible to receive PARPi targeted therapy. Our previous real...
Efficacy outcomes 12 months after initiation of darolutamide in non-metastatic castrate resistant prostate cancer (nmCRPC) from the real world UK multi-centre RECORD study.
83 Background: Darolutamide has authorisation for treatment of non-metastatic Castrate Resistant Prostate Cancer (nmCRPC) based on the ARAMIS trial. The R...
Survival disparities by sex with contemporary advanced urothelial carcinoma (aUC) therapy: A real-world analysis.
670 Background: Retrospective population data suggest poorer survival for female aUC patients. However, data on survival disparities in the era of immuno-...
A phase 1b study of cabozantinib and nivolumab with abiraterone (CABIOS) in metastatic castration-sensitive prostate cancer (mCSPC): Updated safety, efficacy, and immunologic findings.
186 Background: Standard of care for mCSPC typically includes androgen deprivation (ADT) with novel hormonal agents +/- docetaxel. CABIOS is a phase Ib si...
Impact of Medicare Advantage (MA) on timely hormonal intensification in metastatic hormone sensitive prostate cancer.
166 Background: As MA plans gain popularity, covering over half of eligible beneficiaries in 2023, concerns have arisen about their ability to manage comp...
Association between PD-1 expression on tumor-infiltrating regulatory T cells and resistance to first-line nivolumab in advanced clear cell renal cell carcinoma: Insights from the HCRN GU16-260 clinical trial.
590 Background: Inhibition of PD-1 signaling in regulatory T cells (Tregs) has been shown to enhance their immunosuppressive function. We previously demon...
Impaired renal function and cisplatin-based regimens as risk factors for neoadjuvant chemotherapy-induced acute kidney injury in muscle-invasive bladder cancer: A multicenter retrospective study.
760 Background: Neoadjuvant chemotherapy (NAC)-induced acute kidney injury (AKI) is one of the frequent complications in patients with muscle-invasive bla...
Real-world U.S. county-level analysis of erectile dysfunction diagnosis following radiation therapy for localized prostate cancer: The impact of rectal spacer utilization.
365 Background: Rectal spacers have been shown to reduce side effects of prostate radiotherapy (RT) in prostate cancer (PCa) patients in clinical studies....